When a 50-year-old patient developed severe TR just months after receiving a heart transplant, the safest treatment option was to implant an Evoque TTVR device. 

PARTNER 3 has been one of the most closely watched clinical trials in cardiology for many years now. Michael J. Mack, MD, presented a seven-year update during a packed session at TCT 2025. 

Researchers tracked patients for two years, using echocardiography to confirm the devices had completely vanished. Additional studies will still be required.

When the Trump administration requested public input on adding more tariffs for PPE and all medical devices, hundreds of public comments were submitted. One common concern among those responses is that healthcare providers could be left with significantly higher costs. 

TAVR may get more attention, but the Ross procedure has also gained significant momentum in recent years. Ismail El-Hamamsy, MD, PhD, detailed his own team's success with the complex procedure.

The advanced algorithm was designed to detect and evaluate mitral annular calcification on routine, non-gated CT scans. It is now available as part of Carebricks, a generative AI platform from Bunkerhill Health. 

There have been so many developments in the treatment of TR that it can be challenging to keep up. The ACC crafted this new document to help ensure cardiologists, cardiac imagers and other clinicians have access to the most recent clinical data and policy decisions.

ICE is gaining momentum as a helpful imaging option during structural heart interventions, according to a new SCAI position statement. TEE and TTE remain incredibly important, but there are times when ICE can provide the guidance necessary.